Each vial contains a 70 mg blend of GHK-Cu, TB-500 and BPC-157, in lyophilized form.
GLOW combines three peptides that appear across the tissue remodelling literature: GHK-Cu, a copper-binding tripeptide; TB-500, a synthetic fragment of the actin-binding region of Thymosin beta-4; and BPC-157, a synthetic pentadecapeptide.
Each sequence is associated with a distinct reported mechanism: copper transport and collagen gene expression for GHK-Cu, actin sequestration and cell migration for TB-500, and angiogenic and growth factor signalling for BPC-157. Supplying them together supports multi-pathway and comparative study designs that single-peptide preparations do not allow.
Areas of published research
- Collagen and glycosaminoglycan gene expression in dermal fibroblast culture (GHK-Cu)
- Re-epithelialisation rate and capillary density in rodent wound closure models (TB-500)
- Tensile strength and time to recovery in rodent tendon and ligament injury models (BPC-157)
- Comparative and combination study designs examining whether the three pathways interact
For research use only. Not for human or veterinary use. Not a drug, food, or cosmetic.

